Effects of Landiolol, an Ultra-Short-Acting .BETA.1-Selective Blocker, on Electrical Storm Refractory to Class III Antiarrhythmic Drugs
-
- Miwa Yosuke
- Second Department of Internal Medicine, Kyorin University School of Medicine
-
- Ikeda Takanori
- Second Department of Internal Medicine, Kyorin University School of Medicine
-
- Mera Hisaaki
- Second Department of Internal Medicine, Kyorin University School of Medicine
-
- Miyakoshi Mutsumi
- Second Department of Internal Medicine, Kyorin University School of Medicine
-
- Hoshida Kyoko
- Second Department of Internal Medicine, Kyorin University School of Medicine
-
- Yanagisawa Ryoji
- Second Department of Internal Medicine, Kyorin University School of Medicine
-
- Ishiguro Haruhisa
- Second Department of Internal Medicine, Kyorin University School of Medicine
-
- Tsukada Takehiro
- Second Department of Internal Medicine, Kyorin University School of Medicine
-
- Abe Atsuko
- Second Department of Internal Medicine, Kyorin University School of Medicine
-
- Yusu Satoru
- Second Department of Internal Medicine, Kyorin University School of Medicine
-
- Yoshino Hideaki
- Second Department of Internal Medicine, Kyorin University School of Medicine
Search this article
Description
Background: Occasionally it is difficult to inhibit electrical storm (ES) with standard pharmacological treatment. In the present study the effect of landiolol, an ultra-short-acting β1-selective blocker, on ES refractory to class III antiarrhythmic drugs was evaluated. Methods and Results: The study group comprised 42 consecutive patients who developed ES for which intravenous class III antiarrhythmic drugs, such as amiodarone and nifekalant, were ineffective. Landiolol was administered intravenously with an initial dose of 2.5 μg · kg–1 · min–1, which was doubled if it was ineffective, up to a maximum dose of 80 μg · kg–1 · min–1. Landiolol inhibited ES in 33 patients (79%) at a mean dose of 7.5±12.2 μg · kg–1 · min–1. All patients in whom landiolol was ineffective died of arrhythmia. Of the 33 patients in whom landiolol was effective, 25 survived and were discharged (60% of all patients). Landiolol significantly decreased heart rate (P<0.0001), but did not affect blood pressure. Landiolol was not discontinued for adverse effects in any of the responders. Age, APACHE II score, and pH of arterial blood gas differed significantly between the responders and nonresponders. Conclusions: Landiolol is useful as a life-saving drug for class III antiarrhythmic drug-resistant ES. The main mechanism of ES refractory to class III antiarrhythmic drugs could be abnormal automaticity but not reentry. (Circ J 2010; 74: 856 - 863)<br>
Journal
-
- Circulation Journal
-
Circulation Journal 74 (5), 856-863, 2010
The Japanese Circulation Society
- Tweet
Details 詳細情報について
-
- CRID
- 1390282680079465472
-
- NII Article ID
- 10026473315
-
- NII Book ID
- AA11591968
-
- COI
- 1:CAS:528:DC%2BC3cXms1ajsbs%3D
-
- ISSN
- 13474820
- 13469843
-
- PubMed
- 20339194
-
- Text Lang
- en
-
- Data Source
-
- JaLC
- Crossref
- PubMed
- CiNii Articles
-
- Abstract License Flag
- Disallowed